ESMO WCGIC 2023 | Assessing the utility of liquid biopsies in gastrointestinal oncology

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses challenges and limitations in the use of liquid biopsies for patients with gastrointestinal cancers. Liquid biopsies have limited efficacy in early-stage cancers, where studies assessing their utility in this setting are mostly prospective in nature and have short follow-up periods. Further research is also necessary to validate circulating tumor DNA (ctDNA) and minimal residual disease (MRD) as prognostic biomarkers. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.